[{"id":"paper-imerge-imetelstat-mds-lancet-2024","kind":"paper","name":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed","route":"/key-papers/paper-imerge-imetelstat-mds-lancet-2024/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/key-papers/blood-immune-cell.ts","type":"changed","fields":[{"field":"tldr","before":"\"The first telomerase inhibitor to reach approval freed about 40% of heavily transfused MDS patients from transfusions for eight weeks and 28% for six months, versus 15% and 3% with placebo.\"","after":"\"In IMerge, imetelstat, the first telomerase inhibitor to reach approval, freed about 40% of heavily transfused MDS patients from transfusions for eight weeks and 28% for six months, versus 15% and 3% with placebo.\""}]},{"id":"paper-imerge-imetelstat-mds-lancet-2024","kind":"paper","name":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed","route":"/key-papers/paper-imerge-imetelstat-mds-lancet-2024/","commit":"65911992ce","date":"2026-09-08","author":"Jude Gomila","message":"Key papers: haematological malignancies and immune/cell therapy","file":"src/data/key-papers/blood-immune-cell.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"tldr"},{"field":"summary"},{"field":"journal"},{"field":"year"},{"field":"authors"},{"field":"paperType"},{"field":"findings"},{"field":"whatItMeans"},{"field":"caveats"},{"field":"changedPractice"},{"field":"participants"},{"field":"links"},{"field":"cancers"},{"field":"drugs"},{"field":"terms"},{"field":"related"},{"field":"bottlenecks"}]}]